Wednesday, July 8, 2026

pharma · Critical Limb Ischemia (CLI) · Sarcoma · DSGN

Lxo Ireland Designated

Lxo Ireland Designated is a pharma organization headquartered in CARLSBAD, CA, IE. It trades on NYSE under ticker DSGN. Primary therapeutic focus areas include Critical Limb Ischemia (CLI), Sarcoma, Friedreich Ataxia, HP

CARLSBAD, CA, IE HQ
Public company Type
DSGN · NYSE Ticker
Company details
Clinical program

Levodopa

Phase 3 · small molecule · Ischaemic Stroke

Levodopa for Ischaemic Stroke is a Phase 3 program (small_molecule) at Lxo Ireland Designated Activity Company with 1 ClinicalTrials.gov record(s).

Internal code CIRB 2013/323/D

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Lxo Ireland Designated Activity Company
Phase
Phase 3
Modality
small_molecule
Indication
Ischaemic Stroke
Status
completed
Trials
1